Barinthus Biotherapeutics plc.
BRNSDelisted Sep 9, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001828185
Barinthus Biotherapeutics plc. was delisted on Sep 9, 2026; its insiders filed their last Form 4 on Sep 11, 2026; 15 institutions reported holding it in 13F filings for Q2 2026, worth $7.84M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 15
- Q2 2026, +1 vs. previous quarter
- 13F value
- $7.84M
- Reported value at the end of Q2 2026
- Superinvestors holding
- 0
- At the end of Q2 2026
Superinvestors holding BRNS, Q2 2026
No superinvestor reported holding BRNS at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Barinthus Biotherapeutics plc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 28, 2023 (view filing) | Jun 26 | 2 days | Scheeren JosephDirector | PPurchase | +10.0K | $2.44 | +$24.4K | +76.9%23.0K after | |
| Jun 1, 2023 (view filing) | May 25 | 7 daysLate | Wright RobinDirector | PPurchase | +13.8K | $2.66 | +$36.6K | +39.8%48.3K after | |
| Mar 29, 2023 (view filing) | Mar 27 | 2 days | Enright WilliamChief Executive Officer | SSale | −15.0K | $2.42 | −$36.3K | −2.0%728.5K after | |
| Aug 26, 2022 (view filing) | Aug 25 | 1 day | Griffiths GrahamChief Business Officer | SSale | −10.0K | $7.39 | −$73.9K | −8.8%104.2K after | |
| Aug 26, 2022 (view filing) | Aug 24-25 | 2 days | Ellis ChristopherChief Operating Officer | SSale | −39.6K | $6.55 | −$259.6K | −99.8%75 after | 3 lots |
| Aug 19, 2022 (view filing) | Aug 17-18 | 2 days | Ellis ChristopherChief Operating Officer | SSale | −2.82K | $4.82 | −$13.6K | −97.4%75 after | 2 lots |
| Aug 19, 2022 (view filing) | Aug 17 | 2 days | Griffiths GrahamChief Business Officer | SSale | −500 | $4.76 | −$2.38K | −0.4%114.2K after | |
| Aug 17, 2022 (view filing) | Aug 15-16 | 2 days | Ellis ChristopherChief Operating Officer | SSale | −7.55K | $4.77 | −$36.0K | −99.0%75 after | 2 lots |
| Aug 17, 2022 (view filing) | Aug 15-16 | 2 days | Griffiths GrahamChief Business Officer | SSale | −3.62K | $4.77 | −$17.3K | −3.1%114.7K after | 2 lots |
| Aug 15, 2022 (view filing) | Aug 12 | 3 days | Griffiths GrahamChief Business Officer | SSale | −5.00K | $4.50 | −$22.5K | −4.1%118.3K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Barinthus Biotherapeutics plc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| M&G Plc | 5,197,349 | $5.20M | 0.03% | 00.0% | Unchanged |
| SC China Holding Ltd | 1,420,473 | $937.5K | 0.08% | 00.0% | Unchanged |
| GLR Partners, LLC | 1,243,377 | $820.6K | 0.38% | 00.0% | Unchanged |
| DC Funds, LP | 642,204 | $423.9K | 33.82% | 00.0% | Unchanged |
| Rangeley Capital, LLC | 185,136 | $122.2K | 0.12% | +25,671+16.1% | Added |
| Johns Hopkins University | 122,237 | $80.7K | 0.01% | 00.0% | Unchanged |
| Morgan Stanley | 108,843 | $71.8K | 0.00% | +106,633+4,825.0% | Added |
| Baird Financial Group, Inc. | 105,961 | $69.9K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 76,754 | $50.7K | 0.00% | −42,242−35.5% | Reduced |
| HighTower Advisors, LLC | 37,450 | $24.7K | 0.00% | 00.0% | Unchanged |
Holders of 5% or more of BRNS
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Barinthus Biotherapeutics plc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Cawood Frank Wayne | 13G/A | 8.40%3.38M shares | – | Feb 11, 20251 filing | Feb 11, 2025 | SEC |